Perhaps generics seeking NRDL approval for different indications?
Vascepa (icosapent ethyl, a purified ethyl ester of eicosapentaenoic acid or EPA) was first approved by China's National Medical Products Administration (NMPA) in June 2023 for reducing triglyceride levels in adult patients with severe hypertriglyceridemia (=500 mg/dL) as an adjunct to diet. In July 2024, it received additional approval for cardiovascular risk reduction (CVRR) as an adjunct to statin therapy in high-risk adults with elevated triglycerides (=150 mg/dL) and other risk factors, based on the global REDUCE-IT trial.
Market Data 
Markets 
AI
